                                                r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451




                                                                 Revista da
                              ASSOCIAÇÃO MÉDICA BRASILEIRA
                                                             www.ramb.org.br



Original article

Cost-effectiveness of the vaccine against human
papillomavirus in the Brazilian Amazon region夽

Allex Jardim da Fonseca a,b,∗ , Luiz Carlos de Lima Ferreira a,c , Giacomo Balbinotto Neto b,d

a Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, AM, Brazil
b Post-Graduate Program in Economics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
c Post-Graduate Program in Tropical Medicine, Universidade Estadual do Amazonas, Manaus, AM, Brazil
d Instituto de Avaliação de Tecnologia em Saúde, Porto Alegre, RS, Brazil




a r t i c l e       i n f o                    a b s t r a c t

Article history:                               Objective: To assess the cost-utility of the human papillomavirus (HPV) vaccination on the
Received 5 December 2012                       prevention of cervical cancer in the Brazilian Amazon region.
Accepted 23 March 2013                         Methods: A Markov cohort model was developed to simulate the natural evolution of HPV and
Available online 14 September 2013             its progress to cervical cancer, considering the current preventive programs and treatment
                                               costs. The one-year transition probabilities were mainly based on empirical data of local
Keywords:                                      and national studies. The model evaluated the addition of the vaccine to three cervical
Cervical cancer                                cancer-screening scenarios (0, 3 or 10 exams throughout life).
Cost-effectiveness                             Results: The scenario of three Pap tests resulted in satisfactory calibration (base case).
Human papillomavirus                           The addition of HPV vaccination would reduce by 35% the incidence of cervical cancer
Vaccine                                        (70% vaccination coverage). The incremental cost-effectiveness ratio was US$ 825 for each
Brazil                                         quality-adjusted life year gained. The sensitivity analysis conﬁrms the robustness of this
Amazon region                                  result, and duration of immunity was the parameter with greater variation in incremental
                                               cost-effectiveness ratio.
                                               Conclusion: Vaccination has a favorable proﬁle in terms of cost-utility, and its inclusion in the
                                               immunization schedule would result in a substantial reduction in incidence and mortality
                                               of invasive cervical cancer in the Brazilian Amazon region.
                                                                   © 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND


                                               Custo-efetividade da vacina contra o papilomavírus humano na região
                                               Amazônica brasileira

                                               r e s u m o

Palavras-chave:                                Objetivo: Avaliar a custo-efetividade da vacinação contra o papilomavírus humano (HPV) na
Câncer de colo de útero                        prevenção do câncer de colo de útero na região Amazônica brasileira.
Custo-efetividade                              Métodos: Um modelo de coorte Markov foi desenvolvido para simular a história natural do
Papilomavírus humano                           HPV e seu progresso para câncer de colo de útero, considerando os atuais programas de

 夽
   Study conducted at the Universidade Federal de Rio Grande do Sul, Porto Alegre, RS, Brazil, and at the Fundação de Medicina Tropical,
Manaus, AM, Brazil.
 ∗
   Corresponding author.
   E-mail addresses: allex.jardim@bol.com.br, sigilo.coreme@hotmail.com (A.J. Fonseca).
0104-4230 © 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
http://dx.doi.org/10.1016/j.ramb.2013.03.004
                                          r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451                                                 443


Vacina                                     prevenção e os custos de tratamento. As probabilidades de um ano de transição foram
Brasil                                     baseadas principalmente em dados empíricos de estudos locais e nacionais. O modelo
Região amazônica                           avaliou a adição da vacina a três cenários de rastreio de câncer de colo de útero (0, 3 ou
                                           10 exames ao longo da vida).
                                           Resultados: O cenário de três exames de Papanicolau resultou em calibração satisfatória
                                           (caso base). A adição de vacinação contra o HPV reduziria em 35% a incidência de câncer de
                                           colo de útero (70% de cobertura de vacinação). A razão incremental de custo-efetividade foi
                                           US$ 825 para cada ano de vida ajustado para qualidade ganho. A análise de sensibilidade
                                           conﬁrma a robustez deste resultado, e a duração de imunidade foi o parâmetro com maior
                                           variação na razão incremental de custo-efetividade.
                                           Conclusão: A vacinação tem um perﬁl favorável em termos de custo-utilidade, e sua inclusão
                                           no calendário de imunização resultaria em redução substancial de incidência e de mortali-
                                           dade relacionadas ao câncer de colo de útero na região Amazônica brasileira.
                                                                © 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND




                                                                          cost-effectiveness analyses play a key role in the evaluation
Introduction                                                              and selection of strategies that should be implemented.
                                                                              Until the present time, there have been limited data on the
The implementation of screening programs for precursor
                                                                          clinical and economic impacts of HPV vaccination in Brazil,
lesions has reduced mortality due to cervical cancer (CC) in
                                                                          particularly in the Amazon region, where screening programs
developed countries in recent decades; however, infrastruc-
                                                                          have historically not been able to overcome geographical iso-
ture weaknesses and ﬁnancing difﬁculties for this strategy
                                                                          lation and signiﬁcant cultural barriers, as in the case of native
have limited CC control in developing countries.1,2
                                                                          indigenous populations. The present study aimed to conduct
   In Brazil, CC represents an important public health prob-
                                                                          a cost-effectiveness and cost-utility analysis of HPV vaccina-
lem. It is estimated that 22,000 new cases of CC will be
                                                                          tion in the Brazilian Amazon region, an area with high CC
diagnosed in 2013,3 corresponding to an incidence rate of
                                                                          incidence.
17.5 cases per 100,000 women and to a mortality rate of 10.2
deaths per 100,000 women.2 In the Brazilian Amazon region,
the problem is even more serious. Due to a low screening                  Methods
coverage for CC in the target population (less than 25%), a
high incidence of the disease has been registered in that                 Analytical decision model
area (up to 46 cases/100,000 women), similar to the inci-
dence rates in low-income countries, such as Uganda and                   A Markov cohort model was developed as a dynamic, closed,
Mali.4                                                                    and deterministic decision analysis tool for the evaluation of
   The ﬁnding that 70% of CC cases are caused by two                      cost-effectiveness and cost-utility in preventive vaccination
viral serotypes motivated the establishment of preventive                 (Fig. 1), using the TreeAge software (2009 version) (TreeAge
strategies based on vaccination against HPV.5 Currently, two              Software Inc. - Williamstown, MA, USA).
vaccines are available against HPV serotypes 16 and 18.6–8 Vac-               The analysis was performed from the provider’s perspec-
cines are recommended for girls before they engage in sexual              tive (Brazilian Uniﬁed Health System). The target population
intercourse, and they appear to have a satisfactory effective-            was preteen girls (12 years of age), independent of previous
ness. The quadrivalent vaccine induces antibodies of high                 sexual contact or HPV infection. The cohort time horizon
efﬁcacy against HPV and sustains stable levels for at least ﬁve           was lifetime. The model simulated the natural course of HPV
years, in addition to inducing robust immune memory, sug-                 infection until its progression to invasive cervical cancer, tak-
gesting that immunity is enduring.9 Vaccine cross-immunity                ing into account the current prevention programs (Pap test)
has also been documented, with a 40% reduced incidence of                 in Brazil. For each strategy (screening plus vaccination or
pre-malignant cervical lesions induced by other oncogenic                 screening only), the model incorporated health state transi-
HPV serotypes (serotypes 31 and 45).10                                    tion probabilities, and the target population was followed-up
   Many questions have been raised about the role of vac-                 from adolescence until death in a hypothetical cohort.
cination in CC preventive strategies, such as its clinical                    The model incorporated the transition probabilities of
effectiveness, target population, and duration of immunity,               mutually exclusive health states that refer to one-year cycles.
but the main concern addresses the economic implication                   The model simulated the transition probabilities for 70 years
of the vaccine. Unfortunately, the real effects of HPV vacci-             from the age of vaccination (12 years of age). At each
nation on the incidence and mortality rates of CC won’t be                transition, the model attributed the costs, quality of life,
available for decades. In the absence of longitudinal clinical            and death expectation according to the individual’s health
studies that evaluate all of these variables, economic mod-               condition. The transition probabilities were based on empiri-
els of analytical health decisions can be useful tools for the            cal data from the medical literature and referred to transitions
evaluation of preventive strategies, by transporting data from            from a healthy state to a possible HPV infection and low-
empirical studies into real-world simulations, allowing for               grade squamous intraepithelial lesion (LSIL) induction, which
the management of uncertainties and variations. Therefore,                could regress over time to normality, persist, or progress to
444                                              r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451



No vaccine
               M
                   Vaccine                                                     Model parameters and presumption of base case

                                                                               The cohort’s transition probabilities from a state of health to
             Healthy               LSIL                   Death
                                                                               another were established based on data from published stud-
                                                                               ies. Data from studies that evaluated epidemiology of CC in
                                   HSIL                                        the Brazilian population were preferably used to calibrate the
                                                                               model, particularly when addressing the Brazilian Amazon
                                                                               population. The supplementary data illustrate the values of
                             Cervical cancer:
                                                                               the base case, variations of the sensitivity analysis, and the
                               Early stage
                                                                               data source used in the model. The base case values represent
                                                                               the best estimate for each variable.
                             Cervical cancer:
                             Regional stage                                       Where necessary, the model was calibrated by adjusting
                                                                               the incidence of precursor lesions of CC to adequately simu-
                                                                               late the results of cancer incidence as recorded in the Brazilian
                             Metastatic cancer
                                                                               Amazon region.

Fig. 1 – Structure of the Markov decision model. The circle                    Precursor lesions
above represents the decision of whether or not to
vaccinate. The squares represent the states of health, and                     The likelihood of oncogenic HPV-induced precursor lesions
the arrows represent the transition probabilities. Each                        was deﬁned in accordance with a Brazilian study that assessed
individual is followed-up from 12 years of age until death.                    the incidence of squamous intraepithelial lesion in adoles-
At each one-year cycle, the individuals are at risk                            cents who were followed up annually.13
of developing precursor lesions, cancer, or death.                                For simpliﬁcation, LSIL was deﬁned as grade I lesions,
                                                                               and HSIL was deﬁned as grade II and III lesions and in situ
                                                                               carcinoma. The age of sexual initiation was assumed to be
                                                                               13 years according to a local epidemiological study,4 and the
high-grade squamous intraepithelial lesion (HSIL). This, in                    incidence of LSIL peaked one year after the initiation of sexual
turn, could persist, regress to normality, or progress to local-               intercourse.
ized, regional, or metastatic invasive cancer (Fig. 1). Given the                 Due to the paucity of epidemiological studies evaluat-
development of cancer, each individual could continue to suf-                  ing progression probabilities and the regression of precursor
fer from the disease, evolve to death, or evolve to a disease-free             lesions, this model used transition probabilities reported in
state. Each year, individuals would be under an age-speciﬁc                    classic international studies adjusted for one year (one cycle),
risk of death that is unrelated to cancer. The odds of death                   assuming that the mechanism of evolution of the disease is
unrelated to cancer are based on the life expectancy and mor-                  universal.14,15 The probability of precursor lesion regression
tality curves of Northern Brazil.11 The probability of death                   to normality was greater in younger women (< 30 years) com-
unrelated to cancer was calculated through the following for-                  pared to those who were older than 30 years, reﬂecting more
mula:                                                                          persistent infections in older women.16


Probability of death (age) = 1 − [survival probability (age + 1)/              Cytological screening tests

                                 survival probability (age)]                   The probability of detecting an asymptomatic cervical lesion
                                                                               is a function of the percentage of women who undergo Pap
                                                                               smear screening and the sensitivity and speciﬁcity of the test.
    Due to the low coverage of typical preventive vaginal cyto-                Incremental evaluations of vaccinations of the population
logical screening strategies of the Amazonian population, the                  were performed for a non-screening scenario and for scenar-
model was evaluated in three independent scenarios of vacci-                   ios in which individuals were screened three and ten times
nation or non-vaccination.4 The scenario with no cytological                   throughout their lifetimes.
screening throughout life (natural history of HPV infection)                       In the scenario of three screening exams throughout an
was compared with the scenarios for three and ten Pap                          individual’s lifetime, the individuals from the model were sub-
smear exams throughout a woman’s life. At each screening                       jected to the Pap test randomly within the second, fourth, and
event, cervical lesions would be found according to the crite-                 sixth decades of life. In the scenario of ten lifetime exams,
ria (Pap test sensitivity and speciﬁcity) described by national                individuals were subjected to testing every ﬁve years from the
studies. The detection of cervical lesions would require follow-               ages of 25 to 40, and then every three years until the age of
up evaluations or treatment (colposcopy, cryosurgery, and/or                   55, with a ﬁnal exam at 65 years of age, in accordance with
surgery), for which they have been assigned a likelihood of                    a Brazilian study that demonstrated that the frequency of
success, costs, and implications for the quality of life                       preventive examinations tends to be higher between 40 and
of the individuals of the cohort model. The economic analysis                  59 years of age and decreases after 60 years of age.16
adopted a 5% annual discount rate for the cost and out-                            The sensitivity of the Pap test was estimated at 70% for
come, with the intent to convert future values into present                    LSIL and 80% for HSIL. The speciﬁcity ranged from 80% to 90%,
values.12                                                                      according to Brazilian studies.17–20
                                            r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451                                        445


    The fundamental structure of the model is based on clini-               distinguish the effect of the bivalent from the quadrivalent
cal practice consistent with the clinical program procedures                vaccine. The reduction in the incidence of CC-inducing lesions
advocated by VIVA MULHER, a program from the Brazilian                      as a result of vaccination was based on studies that originally
Ministry of Health.21 Abnormal screening examinations were                  reported the effectiveness of the vaccine.6–8
forwarded to colposcopy, and tissues were evaluated by biopsy.                  The vaccination coverage was assumed at 90% of the target
If HSIL was histologically conﬁrmed, then the patient would                 population, based on the results of a recently conducted vacci-
be subjected to cryotherapy treatment or surgery. LSIL cases                nation campaigns against rubella in Brazil (in 2008 and 2011).25
underwent new screening tests after six months.                             In this nationwide vaccination strategy held in a similar pop-
    The costs related to each procedure were derived from the               ulation, the a 95% coverage was achieved among females aged
funds allocation table of the Brazilian Ministry of Health.21,22            between 12 and 19 years. Whereas HPV vaccine requires three
                                                                            applications (unlike rubella vaccine, which requires only one
Invasive cervical cancer                                                    dose), the assumed coverage for this model was slightly lower
                                                                            (90%).
Given the progression to cervical invasive cancer, the proba-                   In the base case of this model, it was determined that the
bilities of its detection in the asymptomatic, early, regional, or          vaccine provided immunity throughout life after three doses.
metastatic stages were derived from a local epidemiological                 However, there are major concerns regarding the duration of
study, as were the costs allocated to the initial treatment of              immunity, with signiﬁcant impact on the economic outcomes
cancer.4 The tumor stages were simpliﬁed as localized can-                  of vaccination. Simulations on the need for booster doses to
cer (FIGO stage I and IIA), regional cancer (FIGO IIB to IVA), or           maintain immunity (one to four doses throughout life) were
metastatic cancer (FIGO IVB). The standardized treatment was                also performed. Booster vaccination required only one dose;
surgery for localized cancer, chemotherapy combined with                    therefore, its cost was estimated at a third of the initial vacci-
radiotherapy for regional cancer, and palliative chemotherapy               nation.
for metastatic cancer.4                                                         There are no references for the price of the vaccine in Brazil
    The probabilities of death by cancer at each stage were                 for the large-scale public sector, since the vaccine has not yet
extracted from the global survival curves of longitudinal                   been incorporated into public health protocols. A study con-
studies.23 The ﬁve-year survival rate ranged from 92.0% for                 duct by the Brazilian Ministry of Health estimated the price
localized cancer to 55.7% for regional cancer and 16.5%                     of vaccination at approximately US$ 180 (US$ 57 for each
for metastatic cancer. The annual incremental costs were esti-              dose + US$ 9 as cost of the applications).26 The Rotative Fund
mated at 10% of the initial value of the cancer treatment                   (Pan-American Health Organization) for vaccine purchases
and refer to screening examinations, control of sequelae, and               has been a technical cooperation mechanism for the expan-
treatment-related toxicities or costs related to tumor recur-               sion of vaccination coverage.27 According to the Rotative Fund,
rence. Only direct costs that were assigned to cancer were                  the cost of the vaccine dose to Brazil would be approximately
computed, and were expressed in American dollars (US$).                     US$ 60 (US$ 17 for each dose + US$ 9 as cost of the appli-
                                                                            cations). In the present model, the cost of initial vaccination
Quality of life                                                             (three doses + implementation costs) for the base case was
                                                                            estimated at US$150.
Utility is a measure of the quality of life; it varies on a scale               However, it was reported that the average price of vaccina-
from 0 to 1, where 0 represents death and 1 represents ideal                tion (three doses) in the American market is US$ 360.28 For the
health. The model multiplies the years of life by the utility               public sector, the value negotiated by the Centers for Disease
implicated in the health status to adjust survival by quality of            Control and Prevention in the United States was US$ 290.29
life; the ﬁnal outcome of effectiveness is quality-adjusted life
years (QALYs). The supplementary data illustrate these values.              Measurement of outcomes
    The completion of the Pap test implied a slight decrease
in the quality of life during the year of examination (0.99),               The results of the effectiveness were shown as the num-
as did colposcopy examinations and conization (0.95). Can-                  ber of cancer cases prevented and deaths avoided, and the
cer precursor lesions of the uterine cervix were considered                 utility outcomes were shown as QALYs. The incremental cost-
asymptomatic and caused no reduction in quality of life.                    effectiveness ratio (ICER) was calculated by the ratio of the
The quality of life (utility) related to each tumor stage was               difference in the cumulative total costs divided by the total
based on an international study that speciﬁcally addressed                  QALYs obtained per woman that are attributed to the addition
this topic using a validated analog scale, and ranged from 0.48             of vaccination to the existing screening program. As a thresh-
(metastatic cancer) to 0.76 (localized cancer).24 The use of util-          old for judgment, the international convention that a strategy
ity parameters from international studies as a reference in the             can be considered cost beneﬁcial if the ICER is less than the
present model can be explained by the absence of Brazilian                  value of GDP per capita (i.e., if the additional cost of a strategy
studies addressing this issue, but may be supported by the                  is less than the value of GDP per capita to save a QALY) was
concept of universality of human suffering.24                               followed.30,31

Vaccination characteristics                                                 Sensitivity analysis

The goal of this model is to evaluate the impact of the vaccine             All economic assessments show a certain degree of
on the incidence of CC exclusively. It was not developed to                 uncertainty, inaccuracy, or methodological controversy.12,31
446                                                   r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451




 Table 1 – Health and economic outcomes for the addition of vaccination to the screening strategy (Pap test).
 Preventive strategies                    Cost per individual         Quality-adjusted life                                    Incremental              QALYs saved                 ICER (US$/QALY)
                                          (US$)                       years (QALYs)                                            cost (US$)               per individual

 Non-screening scenario
  Vaccination                             270                         24.8                                                     -25                      0.2                         Dominant
  No vaccination (natural course)         295                         24.6

 Scenario of three screenings throughout the lifetime (base case)
   Vaccination + screening                320                         29.6                                                     165                      0.2                         825
   Only screening                         155                         29.4

 Scenario of ten screenings throughout the lifetime
   Vaccination + screening                448                         34.5                                                     255                      0.2                         1,275
   Only screening                         193                         34.3


Therefore, sensitivity analyses (one-way) were performed for                           This assessment can be compared to the addition of the
variables with uncertainty over the base case values to assess                      vaccine in other hypothetical scenarios of baseline cytological
the robustness of the present study ﬁndings. These analy-                           screening in Table 1.
ses recalculate the ICER considering the variations in a given                         Fig. 2 compares the reduction in the incidence of CC for
parameter.                                                                          the various strategies (combination of cytological screening
   The evaluated variables were cost of vaccination, effec-                         and vaccination), given the different vaccine coverage levels
tiveness of vaccination, scenario of the pre-existing screening                     simulated by this model. It is noteworthy that the goal of a
program, vaccination coverage, time of immunity, annual dis-                        50% reduction in CC incidence could be achieved by combin-
count rate, and characteristics of the Pap test (sensitivity).                      ing high vaccination coverage (> 70%) with existing screening
For such analyses, the variation values represent the authors’                      procedures (> 3 Pap tests during lifetime).
judgment regarding the uncertainty of the study parameter or
the variations in the results that have been published in the                       Simulation of uncertainties
medical literature.
                                                                                    The sensitivity analyses reveal that vaccination tends to
                                                                                    provide a favorable proﬁle regarding cost-effectiveness,
Results                                                                             despite changes in the base case parameters proposed by the
                                                                                    sensitivity analysis (Fig. 3).
Model calibration                                                                      The population vaccination coverage implies wide varia-
                                                                                    tions in ICER, surpassing US$ 2,000/QALY for vaccine coverage
The primary outcome for the calibration of the model was the                        levels of less than 50%. In a vaccination coverage of 100%, the
incidence of invasive cancer. In the scenario of the natural                        ICER would be approximately US$ 500/QALY. The vaccination
course of HPV infection, without screening exams, the model                         strategy tends to dominate the cytological screening (3x) in
simulated a 4.2% lifetime risk of cancer, which equates to 34.1                     isolation, i.e., it is less costly and more effective (ICER ≤ 0)
invasive CC cases per 100,000 women, considering the demo-                          for vaccination costs lower than US$ 40 (all doses for primary
graphic structure of the region studied.11 In the scenario with                     immunization). For vaccination costs above US$ 500, the vac-
screening three times throughout an individual’s lifetime, the                      cination strategy requires approximately US$ 2,200 to save one
risk of cancer was estimated at 3.4% (equivalent to 27.5 cases                      QALY. A vaccination effectiveness (reduction in the incidence
per 100,000 women).
   The model was well-calibrated to reported data of inci-                                                          80
dence of CC in the Brazilian Amazon. The prediction in the                                                          70
                                                                                    Reduction in CC incidence (%)




three-screenings scenario corresponded satisfactorily to
                                                                                                                    60
the gross incidence rate of invasive CC as recorded in the
                                                                                                                    50
Brazilian Amazon region in 2010 (28.2 cases per 100,000
women), and was considered as the baseline strategy to be                                                           40

compared with the addition of vaccination.4                                                                         30

                                                                                                                    20

Base case analysis                                                                                                  10

                                                                                                                     0
                                                                                                                                               Vaccination only                          Vacc. + Screening 10x
With a vaccination coverage rate of 90%, the vaccination strat-                                                          Screening only                           Vacc. + Screening 3x

egy for preteen girls of the Brazilian Amazon region would                                                                           Vacc. coverage 50%           Vacc. coverage 100%
reduce the lifelong incidence of CC by 42% in this population,                                                                       Vacc. coverage 70%           Pap smear 3x in life
and would reduce the mortality due to CC by approximately                                                                            Pap smear 10x in life
43.4%. The addition of the vaccine would generate an incre-
mental cost of approximately US$ 165 per woman to the                               Fig. 2 – Effectiveness of strategies in the prevention of
current strategy. The incremental cost-effectiveness ratio was                      cervical cancer. Additional effect of vaccination in different
US$ 825/QALY saved, given the base case parameters.                                 vaccine coverage levels and preventive strategies.
                                                                                   r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451                                                                            447


                                         A                                                                                                  B




                                                                                                                        Incremental cost-effectiveness
                                                        4000                                                                                             3000




                       Incremental cost-effectiveness
                                                        3500                                                                                             2500




                                                                                                                              ratio (US$/QALY)
                             ratio (US$/QALY)
                                                        3000
                                                                                                                                                         2000
                                                        2500
                                                        2000                                                                                             1500
                                                        1500                                                                                             1000
                                                        1000
                                                                                                                                                          500
                                                         500
                                                           0                                                                                               0
                                                               30    40       50      60       70   80       90   100                                           0    100      200        300        400        500
                                         C                                    Vaccine coverage (%)                                          D                         Cost of vaccination (US$)




                                                                                                                        Incremental cost-effectiveness
                       Incremental cost-effectiveness




                                                        4500                                                                                             2000
                                                        4000




                                                                                                                              ratio (US$/QALY)
                             ratio (US$/QALY)




                                                        3500                                                                                             1500
                                                        3000
                                                        2500
                                                                                                                                                         1000
                                                        2000
                                                        1500
                                                        1000                                                                                              500
                                                         500
                                                           0                                                                                               0
                                                               0          2          4          6            8    10                                            25    35         45            55         65
                                                                          Annual discount rate (%)                                                                         Vaccine efficacy (%)
                                         E                                                                                                  F
                                                                                                                        Incremental cost-effectiveness   1000
                       Incremental cost-effectiveness




                                                        4000
                                                        3500
                                                                                                                                                          800
                                                                                                                              ratio (US$/QALY)
                             ratio (US$/QALY)




                                                        3000
                                                        2500                                                                                              600
                                                        2000
                                                                                                                                                          400
                                                        1500
                                                        1000
                                                                                                                                                          200
                                                         500
                                                           0                                                                                               0
                                                               0              1            2             3         4                                            50     60           70              80          90
                                                                    Number of booster shoots needed                                                                    Pap test sensibility (%)
                                                                               (life long)

Fig. 3 – Sensitivity analysis. (A) Variation in vaccination coverage (30% to 100%); (B) variation in vaccination cost (US$ 15
to US$ 500); (C) annual discount rate variation (0% to 10%); (D) variation in vaccine effectiveness in reducing the incidence
of pre-malignant lesions (25% to 70%); (E) variation in the number of lifetime booster shots (1-4 booster shots); (F) variation
in the sensitivity of the Pap test (50% to 90%).


of precursor lesions) of above 40% maintains the ICER below
US$1,000/QALY compared to the basal strategy. Increases in
                                                                                                                                   Discussion
the sensitivity of the Pap test tend to modestly increase the
ICER of added vaccination by improving the efﬁciency of the                                                                        Due to increasing healthcare costs worldwide and the growing
baseline strategy, leading to a relative reduction in the addi-                                                                    constraints arising from the scarcity of resources, healthcare
tional beneﬁt of the vaccine.                                                                                                      demands have increasingly sought to justify the incorpora-
   If revaccination is needed (at least one lifetime booster                                                                       tion of a new technique based on its cost-effectiveness or
dose) for the maintenance of immunity, the ICER would be                                                                           cost-utility. To address this growing demand over the past
US$ 1,650/QALY for the vaccination strategy, considering the                                                                       few decades, methodological tools that promote rationality
cost of the vaccine booster at US$ 50 per dose. The need of                                                                        in decision-making in healthcare were proposed, aiming to
extra doses substantially raises the costs of vaccine strat-                                                                       achieve efﬁcient use of available resources.
egy without improving clinical effects, negatively altering                                                                           The present study revealed that the addition of HPV vacci-
the cost-effectiveness proﬁle of vaccination. In the case of                                                                       nation to the existing preventive strategy exhibits a favorable
the need for three booster doses, the ICER would reach US$                                                                         cost-effectiveness and cost-utility proﬁle in the Brazilian Ama-
3,200/QALY. The ICER would surpass US$ 4,000/QALY for the                                                                          zon region. Even when simulating a pessimistic vaccination
hypothesis of a booster dose every 10 years (four booster doses                                                                    coverage rate (approximately 30%), the ICER of the addition of
throughout life).                                                                                                                  vaccination does not exceed the conventional limit of the GDP
   The parameter variation with the greatest impact in the                                                                         value per capita (about US$ 12,000 for Brazil in 2012) for any
ICER was the annual discount rate. In an analysis without a                                                                        other uncertainty simulation. The ICER values resulting from
discount rate, the ICER would be approximately US$ 30/QALY,                                                                        the sensitivity analysis conﬁrms the favorable proﬁle of vacci-
which is substantially less than a discount rate of 10% (ICER =                                                                    nation even if the limit value used were the GDP per capita in
US$ 4,500/QALY). These results are consistent with a lifetime                                                                      the Amazon region (US$ 6,350 per capita). If the cost of vacci-
horizon cohort, as proposed in the present study.                                                                                  nation is reduced to US$ 40 or less, with a vaccination coverage
448                                          r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451



rate of 90%, then adding vaccination tends to dominate the                 acceptance. The cultural acceptance of the vaccine has not
cytological screening strategy used alone.                                 been evaluated in Brazil. It is worth noting that the general
    Some authors have proposed a different limit parameter                 public and health managers’ knowledge of HPV and its impli-
for developing countries, suggesting that an expense of one to             cations are factors that strongly inﬂuence the acceptance of
three times the value of GDP per capita for each QALY saved                the vaccine by a population. Accordingly, strategies of commu-
would represent a good use of resources in these countries.30              nication and education regarding the subject would be crucial
Although there is no consensus in Brazil regarding the limit for           to the success and effectiveness of any public health policy
a strategy to be considered cost-effective, the present study              for the introduction of the HPV vaccine in Brazil, particularly
conﬁrms the favorable proﬁle of the addition of HPV vacci-                 in the Amazon region.
nation in Brazilian regions with poor prevention programs                      There are limitations to the present study. First, due to lack
and a high incidence of CC according to the proposed crite-                of national data, some parameters have been calibrated based
ria.                                                                       on international data. Second, the Markov assumption itself
    To better understand the implications of the HPV vac-                  establishes that transition probabilities depend exclusively on
cine, cost-effectiveness analyses published in countries facing            the current health state, not on a sequence of past health
opposing economic situations can be enlightening. Goldie                   states. Indeed, dynamic transmission models represent an
et al. studied the cost-effectiveness of the HPV vaccine in                economic evaluation methodology that uses probabilistic vari-
72 low-income countries, mostly countries in Africa, which                 ations to more reliably simulate the natural course of diseases
are characterized by high CC incidence rates.32 The analysis               such as CC, but requires large and robust epidemiological
showed that the ICER of adding vaccinations in these countries             data for its preparation (not commonly available). Finally, the
did not surpass US$ 200/QALY in 59 of the 72 countries, but had            present study considered only the effects of the vaccine on
a major impact on the reductions in mortality and incidence                the magnitude of CC, without considering the effects of the
rates of CC after the vaccination of preteens. The analysis                vaccine in reducing other types of cancer, such as those of the
also showed the favorable cost-effectiveness proﬁle of the vac-            vulva, vagina, anus, or head and neck, nor the beneﬁts of the
cine in regions where CC was not controlled by conventional                quadrivalent vaccine on genital warts.
screening programs.                                                            A recent study evaluated the cost-effectiveness of the
    Conversely, in developed countries that succeeded in                   quadrivalent HPV vaccine in Brazil, using a dynamic transmis-
controlling CC incidence and CC-related mortality with                     sion model to assess the effects on CC and genital warts.40
solid gynecological screening programs, the HPV vaccine is                 Kawai et al. estimated that the ICER of vaccination strat-
not as favorable from a cost-effectiveness standpoint Ire-                 egy varied from US$ 448 to US$ 698/QALY when considering
land, the United Kingdom, Switzerland, and Finland have                    only the bivalent vaccine (16 and 18) for control of the CC.
gross incidence rates under 10 cervical cancer cases per                   The study also reported an even better outcome when con-
100,000 women. In these countries, cost-effectiveness stud-                sidering the effect of the quadrivalent vaccine to control
ies showed an additional cost of over US$ 20,000/QALY.33–36                CC and genital warts (US$ 219 to US$ 450/QALY). This data
In the United States, the ICER of adding vaccination exceeded              suggest that, if the additional beneﬁt of vaccine is con-
US$ 43,000/QALY37 . In the Netherlands, the CC incidence rate              sidered, a more favorable cost-effectiveness proﬁle may be
is less than six cases per 100,000 women; however, the ICER                achieved.
of adding the HPV vaccine to the existing Dutch preventive                     The HPV vaccine may also be effective in preventing
program was greater than US$ 70,000/QALY, classifying the                  male cancers (such as those of the penis and anus). Addi-
vaccination strategy, according to the authors, as non-cost-               tionally, male vaccination may improve the protection of
effective.38                                                               women by reducing viral transmission. The cost-effectiveness
    These evidences suggest that the greatest beneﬁt of the                of including Brazilian boys in HPV vaccination was studied
vaccine does not lie in its synergy with the basal population              by Kim et al.41 This strategy rendered a small additional
screening programs, rather in their replacement in countries               gain in clinical beneﬁt (around 4% reduction in risk of HPV-
or regions whose programs are insufﬁcient and poorly struc-                related cancer), but a high additional cost. The authors judged
tured, and have a high prevalence of oncogenic HPV infection.              vaccinating boys as non-cost-effective and recommended that
    Despite the favorable economic proﬁle, the costs involved              efforts should be focused on expanding the coverage of girls
in the vaccination of preteen girls have caused widespread                 only.
concern, especially in developing countries. The HPV vaccine                   The high risk of invasive CC in the Brazilian Amazon region
(16 and 18) is one of the most expensive vaccines on the                   implies an urgent need to rethink the current preventive pol-
market, hindering its incorporation in the healthcare systems              icy, especially for underprivileged regions of the country. The
of countries that would most beneﬁt from this technology.                  present study was the ﬁrst cost-effectiveness analysis of a
According to the lesson learned from the vaccine against hep-              CC preventive strategy directed toward a speciﬁc region of
atitis B, which is now available for children in 89% of the                the country. The cost-effectiveness analysis of HPV vaccine
world’s countries, including the poorest countries, only after             for the Amazon region showed a better proﬁle when com-
a drastic reduction in its price was vaccination in global pro-            pared to studies addressing this topic to Brazil as a whole,
portions possible.39                                                       as in the analysis published by Colantônio et al. (ICER = US$
    Although the cost of the vaccine is the main barrier                   10,181/QALY)42 and by Goldie et al. (ICER = US$ 9,600/QALY).43
to its introduction in Latin America, other factors are also               Regarding public health, these results lead to the conclusion
important, such as the feasibility of vaccinating the tar-                 that public policies on women’s health, particularly on CC
get population, the competition with other vaccines, and its               prevention programs, should be decentralized (adjusted to
                                           r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451                                         449


regional reality) rather than uniform, given the heterogene-
ity inherent in a country of continental proportions, such as
                                                                           Conﬂicts of interest
Brazil.
                                                                           The authors declare no conﬂicts of interest.
    Large-scale preteen vaccination in the Brazilian Amazon
region can be considered an investment in the future to
prevent, in the coming decades, the premature deaths of                    Appendix A.
hundreds of women who have historically been neglected in
preventive government programs.                                            Model parameters, costs, utilities, variation for the sensitivity
                                                                           analysis, and respective sources


Variables                                                                  Base case                 Variation§              Data source
                                                                                                                             (reference)

Properties of vaccination
  Vaccination coverage – three doses (%)                                   90                        30-100                  25

  Vaccination age (years)                                                  12                                                4,13

  Duration of immunity (years)                                             lifetime                  10-lifetime             9

  Adherence to booster vaccination (%)                                     90                                                25


Preventive screening properties
  Number of tests during the lifetime (n)                                  3                         0-10                    4

  Age screening started (years)                                            18                                                estimated
  Sensitivity of Pap test (in LSIL scenario) (%)                           70                        50-90                   17,18

  Sensitivity of Pap test (in HSIL scenario) (%)                           80                        60-90                   19,20

  Speciﬁcity of Pap test (%)                                               90                                                17,18


Transition probabilities
  Develop LSIL after ﬁrst sexual intercourse                                                                                 13

    1st year                                                               0.285                                             4,13

    2nd year                                                               0.117                                             4,13

    3rd year                                                               0.114                                             4,13

    4th year                                                               0.075                                             4,13

    5th to 25th year (mean)                                                0.070 (± 0.022)                                   4,13

    26th to 50th year (mean)                                               0.053 (± 0.012)                                   4,13

    After 51st year (mean)                                                 0.010 (± 0.008)                                   4,13

  Reduction in the probabilities of developing LSIL                        50                        40-70                   6,7,8

  attributed to vaccination (%)
    LSIL regression (< 30 years old)                                       0.193                                             14, 15, 16

    LSIL regression (> 30 years old)                                       0.113                                             14, 15, 16

Develop HSIL from LSIL                                                     0.110                                             14, 15

  Develop invasive cancer from LSIL                                        0.00075                                           14, 15

  Regression of HSIL                                                       0.175                                             14, 15

  Develop invasive cancer from HSIL                                        0.0078                                            14, 15


Invasive cervical cancer properties
  Probability of localized cancer at diagnosis                             0.315                                             4

  Probability of regional cancer at diagnosis                              0.488                                             4

  Probability of metastatic cancer at diagnosis                            0.197                                             4

  Probability of death – localized                                         0.0165                                            23

  Probability of death – regional                                          0.1101                                            23

  Probability of death – metastatic                                        0.305                                             23

Precursor lesions treatment properties
  Effectiveness of cryosurgery for LSIL (%)                                85
  Effectiveness of cryosurgery for HSIL (%)                                75
  Eligibility for cryosurgery (%)                                          85                                                estimated
450                                               r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451



Appendix A (Continued )


Variables                                                                         Base case                Variation§               Data source
                                                                                                                                    (reference)

Others
Duration of cycle (years)                                                         1                                                 estimated
Age of sexual initiation (years)                                                  13                                                4

Discount rate (%)                                                                 5                        0-10                     12, 31

Costs (US$)
  Vaccination – three doses                                                       150                      15 - 500                 26, 27, 28, 29

  Booster shot                                                                    50                                                26, 27

  Pap test                                                                        8                                                 22

  Medical appointment                                                             5.5                                               22

  Colposcopy                                                                      26.8                                              22

  Cryosurgery                                                                     26.8                                              22

  Conization                                                                      498                                               22

  Hysterectomy type 1                                                             1,236                                             22

  Localized invasive cancer treatment                                             3,702                                             4

  Regional invasive cancer treatment                                              8,420                                             4

  Metastatic cancer treatment                                                     2,625                                             4

Utilities
  Normal population                                                               1                                                 estimated
  Completion of Pap test (for 1 year)                                             0.99                                              estimated
  Colposcopy and conization (for 1 year)                                          0.95                                              estimated
  Localized invasive cancer                                                       0.76                                              24

  Regional invasive cancer                                                        0.67                                              24

  Invasive metastatic cancer                                                      0.48                                              24


§ Range of variation addressed in sensitivity analysis of variables where lies any uncertainty. Costs expressed in American dollars (US$).



                                                                                   adenocarcinoma in situ: a combined analysis of four
references
                                                                                   randomised clinical trials. Lancet. 2007;369:1861–8.
                                                                                9. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C,
                                                                                   et al. Induction of immune memory following administration
 1. Zeferino LC, Derchain SF. Cervical cancer in the developing                    of a prophylactic quadrivalent human papillomavirus (HPV)
    world. Best Pract Res Clin Obstet Gynaecol. 2006;20:339–54.                    types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine.
 2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer                          2007;25:4931–9.
    incidence, mortality, and prevalence across ﬁve continents:                10. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE,
    deﬁning priorities to reduce cancer disparities in different                   Hernandez-Avila M, Wheeler CM, et al. The impact of
    geographic regions of the world. J Clin Oncol. 2006;24:2137–50.                quadrivalent human papillomavirus (HPV; types 6, 11, 16, and
 3. Brasil. Ministério da Saúde. Instituto Nacional de Câncer.                     18) L1 virus-like particle vaccine on infection and disease due
    Estimativa 2012: Incidência do câncer no Brasil. [cited 2012                   to oncogenic nonvaccine HPV types in generally HPV-naive
    Jan 15]. Rio de Janeiro: INCA; 2009. Available from:                           women aged 16-26 years. J Infect Dis. 2009;199:926–35.
    http://www.inca.gov.br/estimativa/2012/                                    11. Brasil. Instituto Brasileiro de Geograﬁa e Estatística (IBGE).
 4. Fonseca AJ, Ferreira LP, Dalla-Benetta AC, Roldan CN, Ferreira                 Tábua completa de mortalidade. Brasília (DF): IBGE; 2012.
    MLS. Epidemiology and economic impact of cervical cancer in                    [cited 2012 Mar 13]. Available from: http://www.ibge.gov.br/
    Roraima, a Northern state of Brazil: the public health system              12. Puig-Junoy J, Lopez-Valcarcel BG. Economic evaluations of
    perspective. Rev Bras Ginecol Obstet. 2010;32:386–92.                          massive HPV vaccination: within-study and between study
 5. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S.                      variations in incremental cost per QALY gained. Prev Med.
    Human papillomavirus types in invasive cervical cancer                         2009;48:444–8.
    worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73.                    13. Monteiro DLMM, Trajano AJB, Silva KS, Russomano FB.
 6. The FUTURE II Study Group. Quadrivalent vaccine against                        Incidence of cervical intraepithelial lesions in a population of
    human papillomavirus to prevent high-grade cervical lesions.                   adolescents treated in public health services in Rio de Janeiro.
    N Engl J Med. 2007;356:1915–27.                                                Brazil Cad Saúde Pública. 2009;25:1113–22.
 7. Harper DM, Franco EL, Wheeler CM, Moscicki AB,                             14. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural
    Romanowski B, Roteli-Martins CM, et al., HPV Vaccine Study                     history of cervical squamous intraepithelial lesions:
    Group. Sustained efﬁcacy up to 4.5 years of a bivalent L1                      a meta-analysis. Obstet Gynecol. 1998;92:727–35.
    virus-like particle vaccine against human papillomavirus                   15. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N,
    types 16 and 18: follow-up from a randomized control trial.                    et al. The natural history of human papillomavirus infection
    Lancet. 2006;367:1247–55.                                                      as measured by repeated DNA testing in adolescent
 8. Ault KA, Future II Study Group. Effect of prophylactic human                   and young women. J Pediatr. 1998;132:277–84.
    papillomavirus L1 virus-like-particle vaccine on risk of                   16. Rodriguez AC, Burk R, Herrero R, Hildesheim A, Bratti C,
    cervical intraepithelial neoplasia grade 2, grade 3, and                       Sherman ME, et al. The natural history of human
                                             r e v a s s o c m e d b r a s . 2 0 1 3;5 9(5):442–451                                       451


    papillomavirus infection and cervical intraepithelial                    29. Centers for Disease Control and Prevention. CDC Vaccine
    neoplasia among young women in the Guanacaste cohort                         Price List. [cited 2012Mar 12]. Available from:
    shortly after initiation of sexual life. Sex Transm Dis.                     http://www.cdc.gov/vaccines/programs/vfc/cdc-
    2007;34:494–502.                                                             vacpricelist.htm
17. Girianelli VR, Thuler LC, Szklo M, Donato A, Zardo LMG.                  30. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use
    Comparação do desempenho do teste de captura híbrida II                     of cost-effectiveness analysis in health care resource
    para HPV, citologia em meio líquido e citologia convencional                 decision-making: how are cost-effectiveness thresholds
    na detecção precoce do câncer do colo do útero e de suas                    expected to emerge. Value Health. 2004;7:518–28.
    lesões precursoras no Rio de Janeiro, Brasil. Rev Bras                   31. Devlin N, Parkin D. Does NICE have a cost-effectiveness
    Cancerol. 2004;50:225–6.                                                     threshold and what other factors inﬂuence its decision.
18. Santos ALF, Derchain SFM, Calvert EB, Martins MR.                            Health Econ. 2004;13:437–52.
    Desempenho do exame colpocitológico com revisão por                      32. Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    diferentes observadores e da captura híbrida II no diagnóstico               Health and economic outcomes of HPV 16,18 vaccination
    da neoplasia intra-epitelial cervical graus 2 e 3. Cad Saúde                 in 72 GAVI-eligible countries. Vaccine. 2008;26:
    Pública. 2003;19:1029–37.                                                    4080–93.
19. Gontijo RC, Derchain SFM, Montemor EBL. Citologia oncótica,              33. Szucs TD, Largeron N, Dedes KJ, Raﬁa R, Bénard S.
    captura de híbridos e inspeção visual de lesões cervicais. Cad              Cost-effectiveness analysis of adding a quadrivalent HPV
    Saúde Pública. 2005;21:141–9.                                                vaccine to the cervical cancer screening programme in
20. Tuon FFB, Bittencourt MS, Panichi MA, Pinto AP. Avaliação                   Switzerland. Curr Med Res Opin. 2008;24:1473–83.
    da sensibilidade e especiﬁcidade dos exames citopatológicos              34. Torvinen S, Nieminen P, Lehtinen M, Paavonen J, Demarteau
    e colposcópico em relação ao exame histopatológico na                       N, Hahl J. Cost effectiveness of prophylactic HPV 16/18
    identiﬁcação de lesões intra-epiteliais cervicais. Rev Assoc                vaccination in Finland: results from a modelling exercise. J
    Med Bras. 2002;48:140–4.                                                     Med Econ. 2010;13:284–94.
21. Brasil. Ministério da Saúde. Secretaria de Assistência à Saúde.          35. Dee A, Howell F. A cost-utility analysis of adding a bivalent
    Instituto Nacional do Câncer. Viva Mulher. Câncer de Colo de                 or quadrivalent HPV vaccine to the Irish cervical screening
    Útero: informações técnico-gerenciais e ações desenvolvidas.               programme. Eur J Public Health. 2010;20:213–9.
    Rio de Janeiro (RJ): INCA; 2002.                                         36. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER.
22. Brasil. Ministério da Saúde. Secretaria de Assistência à Saúde.              Adding a quadrivalent human papillomavirus vaccine to the
    Tabela de procedimentos, medicamentos e OPM do SUS.                          UK cervical cancer screening programme: a cost-effectiveness
    Competência Janeiro de 2013. Brasília (DF): MS; 2013.                        analysis. Cost Eff Resour Alloc. 2008;6:4.
23. Surveillance, Epidemiology, End Results (SEER) cancer                    37. Kim JJ, Goldie SJ. Health and economic implications of HPV
    statistics review, 1975-2001. United States National Cancer                  vaccination in the United States. N Engl J Med.
    Institute; 2005. [cited 28 Nov 2010]. Available from:                        2008;359:821–32.
    http://seer.cancer.gov/csr/1975 2001                                     38. Kok IMCM, Ballegooijen MV, Habbema JDF. Cost-effectiveness
24. Myers ER, Green S, Lipkus I. Patient preferences for health                  analysis of human papillomavirus vaccination in the
    states related to HPV infection: visual analogue scales versus               Netherlands. J Natl Cancer Inst. 2009;101:
    time trade-off elicitation. In: Proceedings of the 21st                      1083–92.
    International Papillomavirus Conference. 2004. February                  39. Kane MA. Global implementation of human papillomavirus
    20-26.                                                                       (HPV) vaccine: Lessons from hepatitis B vaccine. Gynecol
25. Brasil. Ministério da Saúde. Portal Saúde. Mulheres atingem                  Oncol. 2010;117 2 Suppl:S32–5.
    meta de vacinação contra rubéola. Brasília (DF); 2008. [cited           40. Kawai K, Araujo GTB, Fonseca M, Pillsbury M, Singhal PK.
    2013 Jan 15]. Available from: http://portal.saude.gov.br/portal/             Estimated health and economic impact of quadrivalent HPV
    saude/visualizar texto.cfm?idtxt=30033                                       (types 6/11/16/18) vaccination in Brazil using a transmission
26. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde.                 dynamic model. BMC Infect Dis. 2012;12:250–9.
    Instituto Nacional de Câncer. Parecer técnico conjunto n◦                41. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys
    01/2011/SVS/SVTIE/SAS/INCA-MS. Brasília (DF); 2011. [cited                   in an HPV vaccination programme: a cost-effectiveness
    2013 Feb 16]. Available from: http://portal.saude.gov.br/                    analysis in a low-resource setting. Br J Cancer. 2007;97:
    portal/arquivos/pdf/parecer tecnico conj n1 2011 hpv.pdf                     1322–8.
27. WPAHO. Pan American Health Organization. 49◦ Conselho                    42. Colantonio L, Gómez JA, Demarteau N, Standaert B,
    Diretor: Fundo Rotativo da Organização Pan-Americana de                     Pichón-Rivière A, Augustovski F. Cost-effectiveness analysis
    Saúde para a compra de vacinas. Washigton (DC); 2009. [2013                  of a cervical cancer vaccine in ﬁve Latin American countries.
    feb16]. Available from: http://www2.paho.org/hq/                             Vaccine. 2009;27:5519–29.
    dmdocuments/2009/CD49-21-p.pdf                                           43. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J,
28. Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human                           O’shea MK, et al. Cost-effectiveness of HPV 16, 18 vaccination
    papillomavirus, vaccines and women’s health: questions                       in Brazil. Vaccine. 2007;25:6257–70.
    and cautions. CMAJ. 2007;177:1–4.
